ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 64

Fibulin-3 In Joint Aging and Osteoarthritis Pathogenesis

Akihiko Hasegawa1,2, Tomo Yonezawa1, Noboru Taniguchi1, Koji Otabe1, Yukio Akasaki1, Tetsuya Matsukawa1, Masahiko Saito3, Masashi Neo4, Lihua Y. Marmorstein5 and Martin K. Lotz1, 1Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, 2Orthopaedic Surgery, Osaka Medical College, Takatsuki, Osaka, Japan, 3Orthopaedic Surgery, Toho University Sakura Medical Center, Sakura, Japan, 4Department of Orthopedic Surgery, Osaka Medical College, Osaka, Japan, 5Department of Ophthalmology and Vision Science, University of Arizona, Tucson, AZ

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Aging, cartilage, chondrocytes and osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Biology and Pathology of Bone and Joint (Cartilage and Osteoarthritis)

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Osteoarthritis (OA) is the most common joint disease. Among the earliest lesions during OA development is disruption of the superficial zone (SZ) of articular cartilage. The SZ of articular cartilage contains adult mesenchymal progenitor cells and is unique in extracellular matrix composition. Recently, we found that the EFEMP1 gene encoding fibulin-3 is specifically expressed in SZ. However, the expression pattern of fibulin-3 in articular cartilage and its role is unknown. The objectives of this study were to examine fibulin-3 expression patterns in joint aging and OA and to investigate the role of fibulin-3 in OA pathogenesis.  

Methods:

Immunohistochemical analysis was performed on human and mouse knee cartilage to determine changes in fibulin-3 expression during joint aging and in OA. To examine the role of fibulin-3 in cartilage homeostasis, experimental OA was induced in wild type and fibulin-3-/-mice. The mice were euthanized 10 weeks after the knee surgery for histological analysis. To address whether fibulin-3 is involved in regulating chondrocyte differentiation, human articular chondrocytes were transfected with fibulin-3-specific siRNA. Cells were harvested at 48 hours and 72 hours for quantitative PCR and Western blot analyses. To further address the role of fibulin-3 during chondrogenesis, bone marrow mesenchymal stem cells (MSC) were transduced with lentivirus (LV) encoding EFEMP1 or control LV expressing LacZ, then MSC pellets were prepared and analyzed for chondrogenesis.

Results:

Fibulin-3 was specifically expressed in the SZ of normal cartilage in human and mouse knee joints. Fibulin-3 expression was intracellular and in the extracellular matrix (ECM) and declined with aging. Both aging-related OA and experimental OA were significantly more severe in fibulin-3-/-mice compared with wild type mice. Fibulin-3 expression was high in MSC and decreased during chondrogenesis. Suppression of fibulin-3 by siRNA in MSC significantly increased SOX9, collagen II and aggrecan in articular chondrocytes, while the overexpression of fibulin-3 inhibited chondrogenesis in MSC.

Conclusion:

We found that fibulin-3 is specifically expressed in the SZ of articular cartilage and its expression is reduced in aging and OA. Fibulin-3 regulates survival and differentiation of adult progenitor cells and its aging-related decline is an early event in OA pathogenesis. Preventing or restoring aging-associated loss of fibulin-3 in SZ chondrocytes has potential to delay or prevent onset of OA.


Disclosure:

A. Hasegawa,
None;

T. Yonezawa,
None;

N. Taniguchi,
None;

K. Otabe,
None;

Y. Akasaki,
None;

T. Matsukawa,
None;

M. Saito,
None;

M. Neo,
None;

L. Y. Marmorstein,
None;

M. K. Lotz,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fibulin-3-in-joint-aging-and-osteoarthritis-pathogenesis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology